This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News for SNY
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
Other News for SNY
Novavax announces regulatory approvals for updated COVID shot
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
Novavax's partners approved for Nuvaxovid formulation for vaccination season
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment
HHS advisors to discuss boosting funding for autism care